Sign inJoin waitlistJoin the waitlist

Lalanthica Yogendran

Division Director · University of Cincinnati Medical Center Inc.

Credentials: · · · ·

History

University of Cincinnati Medical Center Inc.
Present

University of Virginia Medical Center
2021–2022
Hospice and Palliative Medicine
University of Arizona
2020–2021
Neurology
University of Arizona
2016–2020
Richmond University Medical Center
2015–2016
ST GEORGE'S UNIV SCH OF MED, ST GEORGE'S, GRENADA
2006–2010
University of Rochester (Microbiology

Research

Proliferating CD8+ T Cell Infiltrates Are Associated with Improved Survival in Glioblastoma
Cells · 2021 · 62 citations
A Review of Approaches to Potentiate the Activity of Temozolomide against Glioblastoma to Overcome Resistance
Review · International Journal of Molecular Sciences · 2024 · 36 citations
"Doctor, what do i have?" Knowledge of cancer diagnosis among immigrant/migrant minorities
Journal of Cancer Education · 2013 · 25 citations

David Schiff
4 papers
Kyle Wang
4 papers
Rekha Chaudhary
4 papers
Jonathan Forbes
3 papers
Norberto Andaluz
3 papers
Soma Sengupta
3 papers · 1 as a fellow
Timothy Struve
3 papers
Trisha Wise-Draper
3 papers
Akanksha Sharma
2 papers
Camilo Fadul
2 papers
Joel Kaye
2 papers · 2 as a resident
John Breneman
2 papers

Clinical trials

Study of Letrozole in Recurrent Gliomas
Principal investigator · Recruiting · Early phase 1
University of Cincinnati
2017–2027
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2026–2040
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
Site PI · Recruiting · Phase 1, Phase 2
National Cancer Institute (NCI)
2023–2027